Replies to post #171261 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yes a valid argument could be made quite adequately based on the 148 week data. We shall see...

I am just really worried that we might not have bio checked things quite to the standards of the upper echelon of biotech investors- they are very smart you know.

[BIOChecker4]

In my opinion, A2-73 data does not meet the threshold for early approval. Obviously, it will be up to regulators to make this determination, not message board posters with vested interests.

[Jonjones325]

Agreed. Why not go for it? The worse that could happen is they say no. Definitely worth a shot. The ADL scores along with the anecdotal improvements along with Macfarlane’s comments seem to suggest that it’s a path worth pursuing.

Hence, no registration. Yet